Vanda Pharmaceuticals Inc.
VNDA
$3.88
-$0.04-1.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -44.25M | -18.90M | -16.39M | -10.93M | -4.89M |
| Total Depreciation and Amortization | 7.89M | 8.13M | 7.32M | 5.93M | 4.56M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.67M | 1.57M | -4.15M | 1.45M | 4.70M |
| Change in Net Operating Assets | -15.45M | -6.56M | -4.46M | -1.59M | -15.81M |
| Cash from Operations | -56.47M | -15.76M | -17.67M | -5.14M | -11.43M |
| Capital Expenditure | -2.44M | -4.72M | -105.42M | -105.29M | -103.71M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 47.13M | -12.71M | 40.22M | 63.35M | -113.86M |
| Cash from Investing | 44.69M | -17.43M | -65.21M | -41.94M | -217.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -564.00K | -155.00K | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -915.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.48M | -155.00K | -- | -- | -- |
| Foreign Exchange rate Adjustments | -100.00K | -163.00K | 189.00K | -1.00K | -12.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.36M | -33.51M | -82.69M | -47.08M | -229.01M |